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Abstract  27 
 28 
Millions of patients suffer from debilitating spinal cord injury (SCI) without effective treatments. 29 
Elevating cAMP promotes CNS neuron growth in the presence of growth-inhibiting molecules. 30 
cAMP’s effects on neuron growth is partly mediated by Epac, comprising Epac1 and Epac2 – the 31 
latter predominantly expresses in postnatal neural tissue. Here, we hypothesized that Epac2 32 
activation would enhance axonal outgrowth after SCI. Using in vitro assays, we demonstrated for 33 
the first time that Epac2 activation using a specific soluble agonist (S-220) significantly enhanced 34 
neurite outgrowth of postnatal rat cortical neurons and markedly overcame the inhibition by 35 
chondroitin sulphate proteoglycans and mature astrocytes on neuron growth. We further 36 
investigated the novel potential of Epac2 activation in promoting axonal outgrowth by an ex vivo rat 37 
model of SCI mimicking post-SCI environment in vivo and by delivering S-220 via a self-38 
assembling Fmoc-based hydrogel that has suitable properties for SCI repair. We demonstrated that 39 
S-220 significantly enhanced axonal outgrowth across the lesion gaps in the organotypic spinal cord 40 
slices, compared with controls. Furthermore, we elucidated for the first time that Epac2 activation 41 
profoundly modulated the lesion environment by reducing astrocyte/microglial activation and 42 
transforming astrocytes into elongated morphology that guided outgrowing axons. Finally, we 43 
showed that S-220, when delivered by the gel at 3 weeks after contusion SCI in male adult rats, 44 
resulted in significantly better locomotor performance for up to 4 weeks post-treatment. Our data 45 
demonstrate a promising therapeutic potential of S-220 in SCI, via beneficial effects on neurons and 46 
glia post-injury to facilitate axonal outgrowth.   47 
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Significance Statement  48 
 49 
During development, neuronal cAMP levels decrease significantly compared to the embryonic stage 50 
when the nervous system is established. This has important consequences following spinal cord 51 
injury (SCI), as neurons fail to regrow. Elevating cAMP levels encourages injured CNS neurons to 52 
sprout and extend neurites. We have demonstrated that activating its downstream effector, Epac2, 53 
enhances neurite outgrowth in vitro, even in the presence of an inhibitory environment. Using a 54 
novel biomaterial-based drug delivery system in the form of a hydrogel to achieve local delivery of 55 
an Epac2 agonist, we further demonstrated that specific activation of Epac2 enhances axonal 56 
outgrowth and minimizes glial activation in an ex vivo model of SCI, suggesting a new strategy for 57 
spinal cord repair. 58 
  59 
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Introduction 60 
 61 
No cure for spinal cord injury (SCI) exists due to the complex injury nature. Obstacles to SCI repair 62 
include a lack of intrinsic growth capacity of adult mammalian CNS neurons, cavity and glial scar 63 
formation, and inhibitory molecules expressed at SCI lesions including chondroitin sulphate 64 
proteoglycans (CSPGs) and Nogo (Fawcett, 2006; Cregg et al., 2014). Multiple strategies have been 65 
developed to boost the intrinsic growth capacity of adult CNS neurons but without translational 66 
success. For example, neurotrophins enhance axonal regrowth into the lesion in rodent SCI models, 67 
but their inability to overcome inhibitory molecules makes them largely ineffective as a treatment 68 
(Hannila and Filbin, 2008). In adult mice, genetic Klf7 overexpression enhances corticospinal tract 69 
(CST) axonal regrowth into the lesion with pyramidotomy (Blackmore et al., 2012), but fails to 70 
promote regrowth beyond the lesion after SCI (Wang et al., 2017). Genetic PTEN deletion 71 
promotes axonal regrowth beyond the lesion in rodent SCI models (Danilov and Steward, 2015; Du 72 
et al., 2015; Zhou et al., 2015), but potential oncogenesis and long-term harmful effects on neurons 73 
pose concerns (Gutilla et al., 2016; Gutilla and Steward, 2016).  74 
 75 
Elevating cAMP levels has been shown as one of the most effective ways to promote axonal 76 
regeneration and functional recovery in preclinical SCI research (Neumann et al., 2002; Qiu et al., 77 
2002; Nikulina et al., 2004; Costa et al., 2013). Moreover, cAMP elevation overcomes inhibition on 78 
axonal outgrowth caused by myelin-associated inhibitors (Siddiq and Hannila, 2015). However, 79 
targeting cAMP is unlikely to be translated to the clinic as it is ubiquitously expressed, so its 80 
manipulation will alter functions in all types of cells. Therefore, a downstream target of cAMP 81 
more localized to neuronal cells may offer an alternative solution. 82 
  83 
Traditionally, it was thought that cAMP solely signals through protein kinase A (PKA) to manifest 84 
its effects on axonal regeneration. However, the development of more specific tools allowed the 85 
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identification of Epac, a guanine nucleotide exchange factor for Rap1, as an intracellular target, 86 
other than PKA, directly activated by cAMP (Cheng et al., 2008). In fact, a recent study showed 87 
that the cortical infusion of a PKA antagonist, contrary to the traditional hypothesis, led to a 88 
significant increase in functional recovery in rats with SCI, suggesting the involvement of a 89 
different cAMP downstream effector in promoting axon regeneration (Wei et al., 2016).  90 
 91 
In our previous studies, knocking-down intracellular Epac in adult rat dorsal root ganglion (DRG) 92 
neurons using siRNA led to a significant reduction in neurite outgrowth that could not be rescued 93 
by the addition of cAMP analogues (Murray and Shewan, 2008). In addition, chemo-attraction 94 
assays showed that axons are similarly attracted to a gradient of an Epac agonist as they are to a 95 
gradient of a cAMP agonist (Murray et al., 2009). Furthermore, the addition of Epac agonists to an 96 
in vitro SCI remyelination model significantly increased myelination and neurite outgrowth 97 
compared to controls (Boomkamp et al., 2014). Together, these studies suggest that Epac could be 98 
the key protein mediating the positive effects of cAMP on axonal growth and guidance in vitro 99 
(Murray and Shewan, 2008; Murray et al., 2009; Peace and Shewan, 2011b). Epac has two 100 
isoforms: Epac1 is widely expressed embryonically, while Epac2 is restricted mainly to postnatal 101 
nervous tissue (Peace and Shewan, 2011b), suggesting that targeting Epac2 could provide a neuron-102 
specific route for manipulation to enhance axonal growth.  103 
 104 
Therefore, our hypothesis was that the elevation of Epac2 activity by a specific agonist would 105 
enhance neurite outgrowth in vitro and promote axonal outgrowth in an ex vivo model that mimics 106 
the in vivo inhibitory environment after SCI. To achieve a gradual, sustained and local release of the 107 
Epac2 agonist in the injury site we explored the use of a novel self-assembling Fmoc-based 108 
hydrogel as a depot that can be directly injected into the injury site, thus representing a minimally 109 
invasive surgical procedure for future clinical translation (Zhu and Marchant, 2011; Tukmachev et 110 
al., 2016).  111 
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Materials and methods  112 
 113 
All procedures involving the use of live animals and animal tissues were performed in accordance 114 
with the UK Home Office (Scientific Procedures) Act, 1986, and were approved by the local ethics 115 
committee of the University of Aberdeen. 116 
 117 
Cortical neuron culture. Cortices of Sprague Dawley rats at postnatal days 0-1 (mixed sexes) were 118 
harvested as a source for culturing cortical neurons. The tissue was dissociated enzymatically with 119 
50 U/ml papain (Worthington, UK) in Retinal Buffer at pH 7.4 composed of 15 mM HEPES 120 
(Sigma-Aldrich, UK) buffered Hanks Balanced Salts Solution (HBSS; Invitrogen, UK) containing 121 
300 μM D-L cysteine (Sigma-Aldrich, UK) and incubated at 37°C for 30 min. The papain action 122 
was stopped by using 10% Fetal Bovine Serum (FBS; Thermo-Fisher scientific, UK) and cells were 123 
re-suspended in Neurobasal medium (Thermo-Fisher scientific, UK) supplemented with 2% B-27 124 
(Thermo-Fisher scientific, UK), 1% Glutamax (Thermo-Fisher scientific, UK) and 100 U/ml 125 
penicillin and 100μg/ml streptomycin (P/S; Sigma-Aldrich, UK). Cortical neurons were plated at 126 
40000 neurons/ml on round 13 mm glass coverslips (BDH, UK) coated overnight with 10 μg/ml 127 
poly-D-lysine (PDL; Sigma, UK) and cultured for up to 48 h at 37 °C in a 5% CO2 / 95% air 128 
incubator (NU-581DE; Nuaire, USA). 129 
 130 
Dorsal root ganglion (DRG) neuron and explant cultures. DRGs were dissected from SD rats at 131 
postnatal days 0-5 (mixed sexes), collected in Ham's F12 medium (Thermo-Fisher scientific, UK) 132 
and trimmed to remove roots. Explants were plated directly when needed. For dissociating DRG 133 
neurons, ganglia were transferred to 1 ml Retinal Buffer containing 50 U/ml papain as described 134 
above. The tissue was then transferred to 100 μl HBSS containing 0.25 mg/ml trypsin inhibitor 135 
(Sigma-Aldrich, UK) and 50 μg/ml DNAse (Sigma-Aldrich, UK), followed by trituration using a 136 
Gilson P200 pipette until a single cell suspension was achieved. The dissociated neurons were 137 
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diluted to the required density with Neurobasal medium supplemented as described above plus 138 
nerve growth factor (NGF, 100 ng/ml; Sigma-Aldrich UK). DRG neurons were plated at 5000 139 
neurons/ml on 13 mm coverslips coated overnight with PDL as described above and 2 μg/ml 140 
laminin (Thermo-Fisher scientific, UK) and cultured for up to 48 h at 37 °C in a 5% CO2 / 95% air 141 
incubator. 142 
 143 
Microglial and astrocyte cultures. Primary mixed microglia and astrocytes were cultured as 144 
previously described (Georgieva et al., 2018) from the cortices of SD rats at postnatal days 3-6 145 
(mixed sexes) and plated on 10 μg/ml poly-D-lysine (PDL; Sigma-Aldrich, UK) coated 60 mm 146 
Petri dishes (BIOFIL Triple red TCD010060, UK). After four days of incubation at 37 °C in a 5% 147 
CO2 / 95% air incubator, the presence of two layers of cells was confirmed: one layer of astrocytes 148 
firmly attached to the surface of the dish and a layer of microglia visible as large spherical bright 149 
cells on top of the astrocyte layer. For microglia plating, medium was collected after a gentle swirl, 150 
centrifuged at 200 ug for 10 min at 4 °C and the pellet resuspended in warm medium. The microglia 151 
suspension was plated on 18 mm un-coated sterile glass coverslips and used the following day. For 152 
astrocyte plating, once microglial cells were collected, cultures were washed repeatedly with warm 153 
PBS and incubated with trypsin/EDTA 0.25% (Sigma-Aldrich, UK) for 5 min at 37 °C. Trypsin 154 
action was stopped by addition of 10% FBS, centrifuged at 200 ug for 10 min at 4◦C and re-plated 155 
in two PDL-coated flasks. Cultures were maintained for 3 weeks to ensure maturation of the 156 
astrocytes (Smith et al., 1990). Medium was changed every two days and cells were split when 157 
confluent. Microglia and astrocytes were maintained in medium composed of DMEM with 10% 158 
FBS and 100 U/ml penicillin and 100μg/ml streptomycin. 159 
 160 
Soluble agonist and antagonist treatments for neurons in vitro. Soluble agonist Sp-8-BnT-cAMPS 161 
(S-220) and antagonist ESI-05 (both Biolog, Germany) were used according to the manufacturer’s 162 
instructions for specific Epac2 activation and inactivation in neurons, respectively. In some 163 
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experiments, chicken extracellular chondroitin sulfate proteoglycans (CC117; Sigma-Aldrich, UK) 164 
were added to culture media at 0.5 μg/ml at the time of cell plating. 165 
  166 
In vitro treatments for microglia and astrocytes. Mature astrocytes were plated in 13 mm PDL-167 
coated coverslips at a density of 45,000 cells/ml. Microglia were plated in 18 mm uncoated 168 
coverslip at a density of 70,000 cells/ml. Both cells types were allowed to attach and grow 169 
overnight. Next morning, media were changed to serum-free media prior to treatments. Three 170 
conditions were studied: control, Lipopolysaccharide (LPS) and simultaneous LPS and S-220 171 
treatment. Therefore, 10 μg/ml LPS was added to the media alone or together with S-220 at 2.5 μM, 172 
a concentration showing effects in promoting neurite outgrowth. The treatments were left for 4 173 
hours.  174 
 175 
siRNA transfection. For siRNA knockdown, DRG neurons were transfected with 3 μg of siRNA 176 
duplex (Epac2 — ATC CGT GAA TGT AGT CAT TTA) (Qiagen, UK) using the Amaxa 177 
Nucleofector II device (Lonza, UK) according to the manufacturer’s instructions.  To establish 178 
transfection efficiency using this method, 3 μg of 3′-fluorescein-tagged Allstars negative control 179 
siRNA (Qiagen, UK) were transfected into neonatal DRG neurons, which were plated on 2 μg/ml 180 
laminin-coated glass coverslips. After 16 h cells were fixed in 4% paraformaldehyde (PFA; Sigma-181 
Aldrich, UK), immunolabeled using anti-GAP43 and analyzed using a Leica AF6000LX 182 
microscope (Leica, Germany). Fluorescein-labelled neurons were compared to the total number of 183 
GAP43-positive neurons to obtain the transfection efficiency, which was calculated as 80%. 184 
 185 
Lentiviral vector production. We had technical limitations for the construction of lentiviral vectors 186 
carrying the specific Epac2 cDNA, since the available sequence was not suitable for the subcloning 187 
in the lentiviral transfer vector. Therefore, as a proof of concept we constructed Epac-LV as 188 
follows. Human Epac1-YFP construct was kindly provided by Dr. Kees Jalink at The Netherlands 189 
 8 
 
Cancer Institute (Amsterdam, The Netherlands). hEpac1-YFP cDNA was subcloned downstream of 190 
the CMV promoter in the lentiviral transfer vector pRRL. Self-inactivating lentiviral vectors (LV) 191 
were made by co-transfecting HEK293T cells using a three-plasmid system (Dull et al., 1998). 192 
pRRL/hEpac1-YFP or pRRL/GFP plasmids were transfected together with pPACK and pENV 193 
plasmids using the calcium precipitation method (Dull et al., 1998). Lentiviral particles were 194 
harvested 45 h after transfection and concentrated using polyethylene glycol precipitation. Viral 195 
particles were resuspended in sterile PBS after precipitation. The titers were determined by 196 
transduction of HEK293T cells using serially diluted viral stocks. The titers were 4.6 x 109 TU/ml 197 
for LV/hEpac1-YFP (referred as LV/Epac hereafter), and 2.2 x 109 TU/ml for LV/GFP. The viral 198 
stocks were aliquoted and stored at -80°C. Cortical neurons to be transduced with the LV were 199 
plated in 24 well plates (Greiner, UK) at a density of 60,000 cells/ml. 2.2 u 106 TU of LV/GFP or 200 
LV/hEpac1-YFP was added per well to allow transduction. Media were replaced the day after and 201 
then changed every two days. Cells were maintained for 7 days to ensure full expression of the 202 
transgenes. Anti-GFP-labelled neurons were compared to the total number of β‐tubulin-(III) -203 
positive neurons to obtain the transduction efficiency. 204 
 205 
FRET SE microscopy. Fluorescent Resonance Energy Transfer Sensitized Emission (FRET SE) was 206 
performed in live DRG neurons as previously described (Tucker, 2014). FRET SE microscopy 207 
allowed us to demonstrate the level of Epac2 protein activity in the presence of the agonist, S-220, 208 
or the antagonist, ESI-05, respectively, in the growth cones of live DRG neurons. Two fluorophores 209 
(CFP and YFP) were fused to the two termini of Epac2 protein in the Epac FRET construct (see 210 
below). When the distance between the two is <10 nm, which occurs when the protein is inactive, a 211 
FRET signal is produced. On activation of the protein, a conformational change occurs and the 212 
distance between the two fluorophores becomes >10 nm, abolishing the FRET signal. Thus, high 213 
FRET signals correlate with low Epac2 activation and low FRET signals correlate with high Epac2 214 
activation. Briefly, neurons were transfected with the construct mTurqDel-Epac (dDEPCD) 215 
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cp173Venus (d)-Venus (d) (H74) (Klarenbeek et al., 2011) (kindly provided by Dr. Kees Jalink, 216 
The Netherlands Cancer Institute, Amsterdam, The Netherlands) using the Amaxa Nucleofector II 217 
device. The cells were diluted in medium after transfection and cultured in 50 mm glass-bottomed 218 
dishes (MatTek, Ashland, MA) coated with PDL and 5 μg/ml laminin. One day after transfection, 219 
the medium was topped up to 5 ml and buffered with 15 mM HEPES buffer. Using a Leica 220 
AF6000LX imaging system configured correctly for FRET, images were taken of a selected growth 221 
cone in the CFP, YFP and FRET channels every 2 min for a total of 30 min. For each experiment, 222 
the first four images were taken without application to act as a baseline as the system stabilized, 223 
then the reagent was added after the fourth time point. The Epac2 agonist (S-220) was diluted to a 224 
concentration of 5 μM and the antagonist (ESI-05) to 10 μM. Analysis of each image (combining all 225 
3 channels) was carried out using Leica Application Suite-Advanced Fluorescence software by 226 
selecting a ‘region of interest’ within the growth cone and recording the FRET value. These data 227 
were then expressed as a percentage change from time zero. 228 
 229 
Choice Assay. Mature astrocytes obtained as described above were plated at 5000 cells/ml on 5 230 
μg/ml laminin custom-made dishes. These dishes consisted of 60 mm Petri dishes (CellStar® 231 
Greiner Bio-One, UK) that had three 13 mm diameter holes in the base of the dish using a hole 232 
puncher. 18 mm coverslips were mounted onto the base of the dish using RTV 3140 coating glue 233 
(Dow corning, USA) that is non-toxic to cells. Astrocytes were left to grow for 5 h prior to plating 234 
of DRG neurons among the astrocytes. Co-cultures were further incubated at 37qC overnight in a 235 
CO2 incubator. S-220 was added just prior to time-lapse imaging. Time-lapse recordings were taken 236 
over 30 - 60 min using NIS-element software and an okolab chamber mounted Nikon eclipse Ti 237 
inverted microscope. The response of each DRG neurite was categorized into two different 238 
categories - cross over and reflect/retract. Each response was calculated as a percentage of the total 239 
number of interactions in each experimental condition, control or S-220 treatment. Data were 240 
collated for at least 10 growth cones per condition and pooled from at least 3 separate experiments. 241 
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 242 
Growth cone turning assays. Assays were carried out as previously described (Murray and Shewan, 243 
2008). Briefly, DRG neurons were cultured in low-walled glass-bottomed 50 mm Petri dishes 244 
(MatTek, Ashland, MA) coated with 5 μg/ml laminin. The culture medium, supplemented with 15 245 
mM HEPES buffer, was overlaid with a thin monolayer of warmed vegetable oil and transferred to 246 
a Nikon diaphot inverted-stage microscope equipped with a stage-mounted incubator heated to 247 
37°C. Growth cones were visualized using a Nikon diaphot inverted microscope connected to a PC 248 
running QWin version 2.1 software (Leica, Germany). Borosilicate glass micropipettes (Intracel, 249 
UK) were pulled in a Sutter pipette puller (Intracel, UK) so that they had a bore width of 1 μm. 250 
Growth cones were oriented at 45° and 100 μm from a glass micropipette containing 3 - 5 μl of 251 
either F12 as a control or S-220 treatment. Each reagent was ejected by an air pulse of 3 psi at 2 Hz 252 
and 10 ms duration, applied to the pipette by a Picospritzer III (Intracell, UK). Each growth cone 253 
was assayed for 30 min and only growth cones that had advanced at least 10 μm from the original 254 
position at time zero were included. The angle between the position of the growth cone at 30 min, 255 
its original position at time zero, and its original direction of growth was calculated using ImageJ 256 
software. Data were collated for at least 10 growth cones per condition, pooled from at least 3 257 
separate experiments.  258 
 259 
Hydrogel characterization. Fmoc hydrogel is commercially available (BiogelX, UK) and can also 260 
be made using published methods (Alakpa et al., 2016). Hydrogel was prepared at 2.2 mg/ml using 261 
ThinCert™ cell inserts (Greiner Bio-One, UK) and following the manufacturer’s instructions. RGD 262 
(Arg-Gly-Asp) peptide (ab142698; Abcam, UK) at different concentrations was incorporated into 263 
the gel according to the manufacturer’s instructions. Rheology experiments (Discovery HR-2, TA 264 
Instruments) were performed at different time-points during degradation to assess changes in gel 265 
stiffness, using Frequency sweep test 0 to 100 Hz, 1% strain at 37°C. Gels were also weighed at 266 
different time-points during degradation in PBS. Buffer was completely aspirated and the insert 267 
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weight was subtracted from the total weight. The Griess Assay was used to quantify nitrite release 268 
by primary microglia when cultured with the hydrogel for 6 h. LPS (1 μg/ml; Sigma-Aldrich, UK) 269 
was used as a positive activated control. Fluorescein sodium salt (Sigma-Aldrich, UK) was used to 270 
assess the release profile since it has similar molecular weight compared to S-220 (MW = 376.27 271 
Daltons) and can be measured by a fluorescence plate reader (Omega microplate reader; BMG 272 
Labtech, UK) at 440 nm - 520 nm with 700 ms gain (Perale et al., 2012; Wilems and Sakiyama-273 
Elbert, 2015).  274 
 275 
Immunocytochemistry. Cells and explants were fixed with 4% PFA in PBS for 30 min, followed by 276 
incubation with 10% normal goat serum for 1 h, all at room temperature. Cells/explants were then 277 
incubated with primary antibodies overnight at 4°C. We used the following primary antibodies: 278 
anti-β‐tubulin-(III) (1:1000, mouse; RRID: AB_1844090; Sigma-Aldrich, UK), anti-GAP43 (1:500, 279 
rabbit; RRID: AB_10622060; Sigma-Aldrich, UK), anti-GFAP (1:1000, mouse; RRID: AB_94844; 280 
Merk Millipore, UK), anti-Iba1 (1:1000; rabbit; RRID: AB_2314666; Wako), anti-iNOS (1:100; 281 
mouse; RRID: AB_397719; BD Biosciences) and anti-GFP (1:100, chicken; RRID: AB_300798; 282 
Abcam, UK).  Following three washes with PBS, cells/explants were incubated for 2 h at room 283 
temperature with the appropriate secondary antibodies including goat anti-mouse, rabbit or chicken 284 
antibodies (1:400, RRID: AB_221544, AB_221544, AB_143160, AB_141672 and AB_141359; 285 
Invitrogen).  Coverslips were mounted with PBS/glycerol (1:8 ratio) after counterstaining with 286 
Hoechst 33342 (2 μg/ml in PBS; Sigma-Aldrich, UK). All primary/secondary antibodies and goat 287 
serum were prepared with PBS containing 0.2% Triton X-100 (Sigma-Aldrich, UK) and 0.1% 288 
sodium azide (Sigma-Aldrich, UK). 289 
 290 
Imaging and quantification for neurite outgrowth. A Nikon Eclipse Ti-E microscope was used to 291 
acquire all images. HCA-vision (CSiRO) was used to quantify total neurite length. The plugin 292 
Neuron J for ImageJ was used to manually quantify Maximal Neurite Length (MNL) of dissociated 293 
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neurons and maximal distance (Dmax) of neurite growth from DRG explants (Torres-Espin et al., 294 
2014). Analyses were carried out for at least 100 neurons and 10 DRG explants per condition from 295 
three different experiments.  296 
 297 
Analysis of astrocytes and microglia activation in vitro. For each coverslip, ten representative 298 
micrographs were taken with a 20u objective. A minimum of 100 cells per condition were analysed. 299 
The activation of the astrocytes was determined by the quantification of GFAP intensity 300 
(Sofroniew, 2009). All images were converted into 8-bit files and the function threshold in ImageJ 301 
was applied to select only area with GFAP immunoreactivity. Intensity of staining was determined 302 
by the mean optical density value. The mean background fluorescence proximate to each cell was 303 
subtracted from the measured fluorescence intensity of the cell area to give a corrected fluorescence 304 
intensity. The activation of microglia was quantified by calculating the percentage of iNOS/Iba-1 305 
double immunoreactive cells in the total Iba-1 immunoreactive cells. Data for same conditions from 306 
three different replicates were averaged and compared. 307 
 308 
Production of spinal cord slices: ex vivo modelling of SCI. The ex vivo model using rat spinal cord 309 
tissue was adapted from a study using mouse spinal cord tissue (Weightman et al., 2014). The SD 310 
pup’s (postnatal days 0-3; mixed sexes) dorsal trunk skin surface was sprayed with 95% ethanol, 311 
then a dorsal midline incision was made and skin flaps were retracted to expose the spinal column. 312 
A midline incision was made along the length of the spine using fine micro-dissecting Vannas 313 
spring scissors (Fine Science Tools, UK). The spinal cord was rapidly dissected from the 314 
thoracolumbar region and placed in ice-cold slicing media. The meninges were gently removed and 315 
a 0.7-0.9 cm length of cord was cut from the thoracic region. The cord was transferred onto an ice-316 
cold chopping plate of a pre-set McIlwain tissue chopper and sliced lengthways in the parasagittal 317 
plane (350 μm thickness). Three to four slices could be derived from each cord. Slices were 318 
incubated in ice for 90 min, and then selected under a dissecting microscope and transferred to pre-319 
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cut Omnipore membrane ‘confetti’ (Merck Millipore, UK), resting on the Mill cell culture insert 320 
membrane (Merck Millipore, UK), using a plastic Pasteur pipette. The process of slice plating was 321 
carried out under a dissecting microscope to ensure the correct position of the slice. To avoid 322 
variability, the selected slices from each pup were plated together in one dish fitting up to four 323 
slices. Slices were cultured at the air-medium interface for up to 10 days in a humidified incubator 324 
with 5% CO2 at 37°C with 80% medium changes every other day. The experimental unit, n, refers 325 
to slice numbers obtained from different pups. 326 
 327 
Lesioning organotypic spinal cord slice cultures. Cords were lesioned after three days in culture. A 328 
slice lesioning tool was custom-made using a pre-assembled, double-bladed scalpel with a spacer 329 
creating a gap of approximately 700 μm. The tool was aseptically assembled prior to lesioning by 330 
taping together two surgical blades (size 15) with a spacer in the middle secured into a scalpel 331 
holder. The same lesioning tool was used in each individual experiment. The lesioning procedure 332 
was implemented inside a horizontal laminar flow hood under a dissecting microscope. To stabilize 333 
the slice in the process of lesioning the confetti was cut in a T shape allowing it to be secured with 334 
forceps while producing the lesion. A small lateral movement was used to ensure complete 335 
transection of the cord without damaging the confetti. An aspirator fitted with a pipette tip was used 336 
to remove all the debris resulting from the lesioning. 337 
 338 
Assessment of the viability of spinal cord slices. To assess viability, three intact slices were 339 
randomly chosen before and after the lesion and incubated with the live/dead assay kit (Invitrogen, 340 
UK) containing calcein (1 μl/ml) for live cells and ethidium bromide (3 μl/ml) for dead cells, for 15 341 
min at 37ºC. Following the incubation period slices were mounted with antifade mounting media 342 
Vectashield (Vector Laboratories, UK). Immediately afterwards, fluorescence micrographs were 343 
taken (664 μm x 834 μm) with a 10X objective with consistent exposure settings and converted to 344 
grey sale. The integrated density (mean grey value per unit area) was measured from both live- and 345 
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dead-stained micrographs. Thus, the viability for each slice was calculated by expressing the 346 
corrected integrated density of the live-stained micrograph as a percentage of the sum total from 347 
both stained groups (Cho et al., 2009). The quantification was conducted using ImageJ software. 348 
 349 
Treatment of spinal cord slice. Treatment was administered immediately after the lesion either in 350 
the medium or incorporated into the gels. Treatment gels were prepared 2 h before lesioning and 351 
pre-cut into 700 μm x 700 μm pieces using the McIlwain tissue chopper. Gels were incorporated 352 
into the injury site under the microscope using needles. Treatment was applied for 7 days.  353 
 354 
Immunohistochemistry. All slices were fixed with 4% PFA 7 days after the lesion for 30 min, 355 
followed by incubation with 10% normal goat serum for 1 h at room temperature. Slices were then 356 
incubated with primary antibodies for 24 h at 4°C. Primary antibodies used were: anti-β (III)‐357 
tubulin (1:1000, mouse;), anti-GFAP (1:500, rabbit; RRID: AB_2109645; Merk Millipore), anti-358 
GFAP (1:1000, mouse), anti-Nestin (1:400, mouse; RRID: AB_2151130; Merk Millipore), and 359 
anti-Iba1 (1:1000; rabbit).  Following three washes with PBS, cells were incubated for 4 h at room 360 
temperature with appropriate secondary antibodies including goat anti-mouse or rabbit secondary 361 
antibodies. Slices were mounted with Vectashield. All primary/secondary antibodies and goat 362 
serum were prepared with PBS containing 0.2% Triton X-100 and 0.1% sodium azide. 363 
 364 
Image and axonal outgrowth analysis on spinal cord slices. All fluorescence images were captured 365 
with a Nikon Eclipse Ti-E microscope. Single panoramic images were generated when appropriate 366 
using the Large Image tool in Nis Elements for advanced research software. Maximal Intensity 367 
Projection images using multiple Z planes were also used when appropriate. Where applicable, 368 
fluorescence images of immunostained slices were merged using Photoshop. Quantitative analysis 369 
of E-tubulin-III stained profiles was conducted across the lesion gap from one lesion margin to the 370 
other according to previously published methods (Weightman et al., 2014), with 20 division lines at 371 
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an equal distance of 35 μm between each line using a multi-selection plugin from ImageJ. Peak 372 
analysis plugin from ImageJ was then used to convert the staining into optical density (OD) at each 373 
division line covering the whole width of the lesion gap, which is equal to the width of the slice. 374 
Finally, the peaks (number of staining profiles) per mm2 per slice (Weightman et al., 2014) were 375 
calculated by averaging the ODs and then divided by the area of the lesion gap.  376 
 377 
Analysis of astrocyte activation in spinal cord slices. Quantitative analysis of astrocyte activation 378 
was conducted by semi-quantification of GFAP staining intensity within the lesion gap. Thus, three 379 
fluorescence images (478 μm x 598 μm) were taken with a 20u objective from the front areas of the 380 
GFAP-immunoreactive glial scar from one half of the lesion first: the central one aligned with the 381 
mid-line perpendicular to the lesion margin and then one right and one left with equal distance of 382 
200 μm from the central one. We then repeated with another three fluorescence images for the other 383 
half of the lesion as described above. Consistent exposures were applied for all captured images, 384 
which were then converted to greyscale followed by applying a threshold using the ROI manager 385 
plugin from ImageJ. Finally, the intensity of the GFAP staining from the six images per slice was 386 
averaged.  387 
 388 
Reactivity of astrocytes was also estimated by the overlapping of GFAP and Nestin as previously 389 
described (O'Neill et al., 2017). Thus, three fluorescence images (478 μm x 598 μm) were taken 390 
with a 20u objective from the front areas of the GFAP-Nestin immunoreactive glial scar from both 391 
halves of the lesion as described above. Briefly, captured images were converted to greyscale 392 
followed by the application of the “auto-threshold” function using the “Default” setting in ImageJ. 393 
This generates a binary image with a black signal in a white background. “Image Calculator” 394 
function in ImageJ using the “AND” operation was used to generate a third image representing the 395 
regions of overlap between binary green and red. The number of overlapping pixels was calculated 396 
by using the “Histogram” function in ImageJ to obtain the total number of pixels with value 255 397 
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(black). A minimum of three images was analyzed per spinal cord slice and averaged to get a final 398 
value per slice.  399 
 400 
Analysis of microglial activation in spinal cord slices. Quantitative analysis of microglial activation 401 
was conducted by semi-quantification of the cell body perimeter of Iba-1 immunoreactive cells 402 
within the lesion gap. Thus, three fluorescence images (316 μm x 395 μm) were taken with a 30u 403 
objective as described above for astrocyte activation analysis. The perimeter (Kozlowski and 404 
Weimer, 2012) of at least 20 Iba-1 immunoreactive cells per micrograph was then measured using 405 
ImageJ and averaged for each slide. For non-lesioned microglial activation analysis, three images 406 
were taken from at least 1 mm away from the lesion site, where Iba-1-immunoreactive cells 407 
displayed non-reactive morphologies.  408 
 409 
Treatment of contusion injured spinal cord with S-220-loaded hydrogel. For all in vivo experiments, 410 
young male adult Wistar rats weighing between 180 - 200 g were purchased from Envigo 411 
(Shardlow, United Kingdom). The skin and muscle overlying the spinal column were incised and a 412 
laminectomy was performed between the T9 and T10 levels. Following fixation of the adjacent T9 413 
and T11 vertebral body to suspend the target region, a standardized moderate (12.5 mm) thoracic 414 
spinal contusion was inflicted at T10 thoracic vertebral level by the use of a NYU impactor device 415 
(MASCIS rat model III; Rutgers University, New jersey, US) as previously described (Young, 416 
2002; Kjell and Olson, 2016). Following the injury, muscle layers were sutured and the skin was 417 
closed. Post-interventional care included manual voiding of the bladder twice a day until voiding 418 
reflex was regained. Three weeks after the induction of the injury rats were randomly allocated to 419 
treatment groups. For rats receiving treatment a 10 μl Hamilton syringe was loaded with the pre-gel 420 
format of the hydrogel using RN 26S gauge needle (26S/102/pst2/tapY) (Hamilton; Supelco, USA). 421 
The Hamilton syringe was mounted on a stereotaxic frame and armed into 45º angle. The dura was 422 
opened, and the needle was introduced into the dura with the fine controllers. A maximum of 3 μl 423 
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was injected at1 μl/min. The needle was left in place for 10 min after injection to prevent the 424 
leakage of the pre-gel solution. The dura was covered with a piece of saline-soaked gel foam, 425 
muscle layers were sutured and the skin was closed. Buprenorphine (0.3 mg/kg; Vetergesic®; 426 
Alstoe Animal Health, UK) was given s.c. for the management of acute pain after surgery and 427 
saline (0.9 % NaCl, 5 ml) was administered s.c. to compensate for any blood loss. Locomotor 428 
function was assessed by two observers independently using the 21-point Basso, Beattie & 429 
Bresnahan (BBB) open field locomotor scale on post-op days 1, 3, 14, 21, 28, 35, 42, 49.  430 
 431 
Statistical analysis. Sigma Plot 13.0 and Origin Pro 2018b software were used for all statistical 432 
analyses. The normality test Shapiro-Wilk was performed to ensure normal distribution of the data 433 
and suitability of parametric tests. Equal variance was tested using the Brown-Forsythe test. 434 
Statistical analyses were performed using Unpaired Student’s t test and one-way ANOVA, using 435 
Bonferroni’s multiple comparison test for post-hoc analysis. If normality was not met, non-436 
parametric tests were used: the Mann-Whitney rank sum test and the Kruskal-Wallis One-way 437 
ANOVA on ranks with Dunn's method or Tukey test post hoc correction. For in vitro studies, all 438 
data represent mean ± standard error of the mean (SEM). 439 
 440 
For ex vivo studies, between 4 and 6 replicates were done per condition and experiment and are 441 
represented by a circle in the quantification graph. All values quoted are expressed as the mean ± 442 
SEM (box limits) ± 5% - 95% (error bars). Two-way repeated-measure ANOVA was performed for 443 
locomotor recovery (BBB scale) analysis, followed by Bonferroni’s post-hoc multiple comparison 444 
adjustment to calculate the significant levels. “Treatment” is a between-subjects variable, while 445 
“time” is a within-subjects variable. The in vivo data were presented as means ± SEM. All statistical 446 
analyses were performed using Origin Pro 2018b and SigmaPlot 14.0 software. Statistical 447 
significances are indicated as p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). 448 
 449 
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Results 450 
 451 
The elevation of Epac2 activity enhances neurite outgrowth in vitro  452 
Axonal repair following SCI requires the restoration of relays from higher brain centers, such as 453 
corticospinal tracts, as well as ascending sensory pathways relaying information from the periphery to 454 
the brain. We have expertise in model systems involving cortical neurons and DRG neurons and have 455 
used both neuronal types in the current study. 456 
 457 
Using cultured postnatal rat cortical neurons, we found that neurite outgrowth, i.e. mean total neurite 458 
length per neuron, was significantly enhanced by the treatment of S-220 at 2.5 μM for 24 h, when 459 
compared to that of the controls (agonist vs control: 97.5 ± 4.1 vs 72.8 ± 2.6 Pm, p = 0.0002, unpaired 460 
Student’s t test; Fig. 1A-C). Moreover, neurite outgrowth was significantly inhibited by bath application 461 
of ESI-05 at 10 μM for 24 h in culture (antagonist vs control: 50.1 ± 4.8 vs 77.8 ± 4.8 Pm, p = 0.018, 462 
unpaired Student’s t test; Fig. 1D-F). Furthermore, we used genetic tools such as siRNA and lentiviral 463 
vectors to illustrate the importance of Epac for neuronal growth. Thus, cortical neurons subjected to 464 
specific Epac2 siRNA knockdown for 48 h showed significantly shorter total neurite length in 465 
comparison with that of the controls (siRNA vs control: 131.4 ± 19.9 vs 183.3 ± 24.3Pm, p = 0.018, 466 
unpaired Student’s t test; Fig. 1G-I). Similar results were also obtained for postnatal rat DRG neurons 467 
when they were treated with the S-220 (S-220 vs control: 991.9 ± 202.9 vs 399.2 ± 101.4 Pm, p = 468 
0.005787, unpaired Student’s t test; data not shown) or when they were transfected with Epac2 siRNA 469 
(siRNA vs control: 889.7 ± 49.9 vs 1677.9 ± 105.6 Pm, p= 1.1x10-11 unpaired Student’s t test; data not 470 
shown). Cortical neurons were transduced with lentiviral vectors (96.7 ± 3.4 % transfection efficiency) 471 
and left to grow for 7 days to ensure protein expression. Neurons transfected with LV/Epac-YFP had 472 
significantly more neurite outgrowth when compared to that of LV/GFP transduced neurons (LV/Epac-473 
YFP vs LV/GFP: 1229.2 ± 20.0 vs 795.2 ± 110.4 Pm, p = 0.003, unpaired Student’s t test; Fig. 1J-L).  474 
 475 
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Epac2 agonist activates Epac protein in DRG growth cones and attracts growth cones 476 
To demonstrate the activation/deactivation of Epac protein by the soluble agonist S-220 and antagonist 477 
ESI-05 in neuronal growth cones, we performed FRET SE microscopy, which allowed the visualization 478 
of protein dynamics in situ (Tucker, 2014). DRG neurons were transfected with mTurqDel-EPAC 479 
(dDEPCD) cp173Venus (d)-Venus (d) (׽40% transfection efficiency) and allowed to grow for 48 h 480 
before the experiments were performed. We found that there was a significant increase of Epac 481 
activation in growth cones during the 30 min when the S-220 was applied (S-220 vs baseline, p = 8 x10-482 
8, unpaired Student’s t test; Fig. 2A-B, E). Conversely, when ESI-05 was applied, we found significantly 483 
reduced Epac activation in the growth cones when compared to the baseline (ESI-05 vs baseline Epac2, 484 
p = 0.001, unpaired Student’s t test; Fig. 2C-D, E). Using the growth cone turning assay we examined 485 
the effect of asymmetric Epac2 activation on neonatal rat DRG neurites by creating a gradient of the S-486 
220 agonist. Fig. 2H showed that neonatal DRG growth cones displayed a random response to a gradient 487 
of F12 culture media emitted from a micropipette placed at a 45º angle to the initial orientation of the 488 
projecting growth cones, with a mean turning angle of -1.92º ± 0.05º at 30 min. In contrast, growth 489 
cones displayed a strong chemoattraction when S-220 was emitted from the pipette (Fig. 2F-G), and the 490 
mean turning angle of 12.7º ± 4.1º at 30 min was significantly greater than that of F12 culture media (p 491 
= 0.045, unpaired Student’s t test; Fig. 2H). 492 
 493 
The elevation of Epac2 activity overcomes inhibitory effects on cortical neuron growth in vitro 494 
To further explore the potential of Epac2 activation as a promising strategy to promote axonal outgrowth 495 
in the post-SCI environment, we cultured postnatal rat cortical neurons together with CSPGs, which 496 
significantly inhibited the outgrowth of cortical neurons by 32.1 ± 8.7% as compared to the controls (p = 497 
0.003, Mann-Whitney Rank Sum test; Fig. 3A-B, D). S-220 treatment was able to overcome the 498 
inhibitory effect of CSPGs on the mean total neurite length per cortical neuron (CSPGs + S-220 vs 499 
CSPGs: 32.1 ± 8.7 vs 8.7 ± 3.3%, p = 0.007, Mann-Whitney Rank Sum test; Fig. 3B-D). We then 500 
analyzed the response of the growth cones of DRG neurons when they encountered inhibitory mature 501 
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astrocytes. This assay was performed in DRG neurons as it was optimized for this primary neural type. 502 
The growth cones had the choice of either growing over astrocytes or remaining on the laminin substrate 503 
during a period of 30 min time-lapse. Growth cone response behaviors were classified into two 504 
categories: retract/reflect and crossover, respectively (Fig. 3 E-F). When S-220 was added to the co-505 
cultures, we found a significantly increased proportion of growth cones growing over astrocytes in 506 
comparison to that of the controls (S-220 vs control: 45.7 ± 10.3 vs 11.2 ± 4.2%, p = 0.0216, unpaired 507 
Student’s t test; Fig. 3G). Conversely, we found a significant reduction in the proportion of 508 
retracting/reflecting growth cones (S-220 vs control: 54.3 ± 10.8 vs 88.8 ± 8.7%, p = 0.0306, unpaired 509 
Student’s t test; Fig. 3G). 510 
 511 
The elevation of Epac2 activity by S-220 modulates LPS-activated astrocytes and microglia  512 
In order to assess whether S-220 has an effect in preventing and/or modulating the activation of the 513 
astrocytes and microglia in vitro, we perform a simultaneous treatment study in which S-220 was given 514 
at the same time with 10 μg/ml LPS. Previous experiments in the lab demonstrated that the treatment of 515 
10 μg/ml LPS for four hours allowed rapid activation of the microglia and astrocytes cells without 516 
inducing apoptosis (Georgieva, 2018).  517 
 518 
The mean GFAP expression of astrocytes treated with LPS (Fig. 4B) was increased compared to controls 519 
(Fig. 4A) (LPS vs control: 27.9 ± 1.8 vs 18.4 ± 0.9, p = 3x10-6, one-way ANOVA, Bonferroni’s post 520 
hoc; Fig. 4G). The simultaneous treatment of LPS and S-220 (Fig. 4C) showed a significant reduction of 521 
GFAP intensity compared with LPS-treated astrocytes (LPS + S220 vs LPS: 20.7 ± 0.8 vs 27.9 ± 1.8, p = 522 
2x10-4, one-way ANOVA, Bonferroni’s post hoc; Fig. 4G), being not significantly different to that of the 523 
control ones (LPS + S220 vs control: 20.7 ± 0.8 vs 18.4 ± 0.9, p = 0.57, one-way ANOVA, Bonferroni’s 524 
post hoc; Fig. 4G). Astrocyte morphology was different within groups. LPS treated astrocytes (Fig. 4B) 525 
became reactive, characterized by hypertrophic processes, broader cell bodies and tend to cluster 526 
 21 
 
together. When astrocytes were simultaneously exposed to LPS and S-220 (Fig. 4C), they preserved 527 
non-reactive morphology with slender processes similar to that of the control (Fig. 4A). 528 
  529 
Microglia reactivity was quantified as the percentage of iNOS marker immunoreactivity. The percentage of 530 
iNOS expression of microglia treated with LPS (Fig. 4E) was increased compared to controls (Fig. 4D) 531 
(LPS vs control: 45.8 ± 2.9 vs 4 ± 1.3, p = 1.5x10-16, one-way ANOVA, Bonferroni’s post hoc; Fig. 4H). 532 
The simultaneous treatment of LPS and S-220 (Fig. 4F) showed a significant reduction of percentage of 533 
iNOS expression compared with LPS-treated microglia (LPS + S220 vs LPS: 24.7 ± 3.8 vs 45.8 ± 2.9, p 534 
= 3.4x10-6, one-way ANOVA, Bonferroni’s post hoc; Fig. 4H), being also significantly different to that 535 
of the control ones (LPS + S220 vs control: 24.7 ± 3.8 vs 4 ± 1.3, p = 6.1x10-6, one-way ANOVA, 536 
Bonferroni’s post hoc; Fig. 4H). Moreover, the simultaneous treatment of LPS and S-220 showed a 537 
significant reduction of nitrite release compared with LPS-treated microglia (LPS + S220 vs LPS: 0.7 ± 538 
0.2 vs 11.8 ± 0.9, p = 0.0002, unpaired Student’s t test; Fig. 4I). 539 
 540 
Fmoc-based hydrogel shows suitable properties for spinal cord repair 541 
Self-assembling Fmoc-based hydrogel was used as a delivery depot for S-220 agonist and therefore, its 542 
suitability for spinal repair needed to be tested. The hydrogel (Fig. 5A) at 2.5 mM had a stiffness of 543 
׽100 Pa (Fig. 5C). We found that the hydrogel degraded gradually in vitro in PBS at 37°C, which was 544 
manifested by the reduction in gel stiffness [(H (2) = 95.27, p = 2 ×10-14, Kruskal-Wallis ANOVA on 545 
Ranks with Tukey post hoc; Fig. 5C] and gel mass over time [one-way ANOVA (F (4,25) = 50.087, 546 
p=1.4 ×10-11 with Bonferroni’s post hoc; data not shown]. Minimal activation of gel-exposed microglia 547 
was found by measuring nitrite release in culture media, contrasting to the significant nitrite release 548 
observed using activating agent LPS alone (Fig. 5B). Using fluorescein, which has a similar molecular 549 
weight compared to the Epac2 agonist, we estimated the cumulative release of the agonist from the 550 
hydrogel (Perale et al., 2012; Wilems and Sakiyama-Elbert, 2015). The hydrogel showed a two-phase 551 
release profile over a 28-day period, i.e. a quick release during the first 7 days followed by a minimal 552 
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gradual release over the next three weeks (Fig. 5D). The hydrogel can also incorporate functional motifs 553 
such as arginine-glycine-aspartate (RGD) peptides to promote cell adhesion (Zhou et al., 2009). Here, 554 
we demonstrated that the hydrogel can be functionalized with RGD peptides at different concentrations, 555 
with the 1.6 mM being the optimal for neurite outgrowth (Dmax) of postnatal rat DRG explants 556 
[(F(3,16)= 7.06, p = 0.003; No-RGD vs 1.6 mM RGD: 535 ± 3 vs 975 ± 3 Pm, p = 0.0035; No-RGD vs 557 
3.2 mM RGD: 535 ± 29 vs 839 ± 60 Pm, p = 0.0039; one-way ANOVA with Bonferroni’s post hoc; Fig. 558 
5E-H]. At this optimal concentration of RGD, we observed that the 2-D neurite outgrowth of dissociated 559 
postnatal rat DRG neurons, i.e. maximal neurite length per neuron, was comparable to that seen in gels 560 
without RGD (31.8 ± 5.2 vs 24.5 ± 3.8 μm, p = 0.137, unpaired Student’s t test; data not shown). 561 
However, we found significantly increased 2-D neurite outgrowth of postnatal rat cortical neurons with 562 
gels functionalized with 1.6 mM RGD, when compared to that of non-functionalized gels (71.4 ± 9.2 vs 563 
17.3 ± 4.3 Pm, p = 1.2 x10-6, unpaired Student’s t test; Fig. 5I-K). Furthermore, we observed that the 564 
functionalized hydrogel supported excellent 3-D neurite growth of DRG explants and DRG neurons 565 
(Fig. 5L-N). For simplicity, we refer to the hydrogel functionalized with 1.6 mM RGD hereafter as “the 566 
hydrogel”. 567 
 568 
The elevation of Epac2 activity enhances 2-D neurite outgrowth with Fmoc hydrogel in vitro 569 
As a proof-of-concept, we first explored combination of the Epac2 activation strategy with the gel by 570 
adding the S-220 agonist in the media of cultures where DRG explants or DRG neurons grew on the gel 571 
surface. We demonstrated that there was a significant increase in neurite outgrowth of DRG explants 572 
growing on the gel and simultaneously treated with the agonist when compared to that with the gel alone 573 
[S-220 + gel vs gel only: 1141.4 ± 159.9 vs 608.3 ± 93.9 Pm (Dmax), p = 0.029, unpaired Student’s t 574 
test; Fig. 6A-C]. In addition, we found that the neurite outgrowth of dissociated DRG neurons was 575 
significantly enhanced by combining S-220 and the gel in comparison to that of the gel alone [S-220 + 576 
gel vs gel only: 57.3 ± 6.5 vs 31.9 ± 5.3 Pm (mean total neurite length per neuron), p = 0.002, unpaired 577 
Student’s t test; Fig. 6D-F]. 578 
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 579 
 580 
 581 
The elevation of Epac2 activity promotes axonal outgrowth in an ex vivo model of SCI 582 
To further demonstrate the potential of Epac2 activation for spinal cord repair, we adapted a previously 583 
established mouse ex vivo model of SCI using postnatal rat spinal cord organotypic slices (Weightman et 584 
al., 2014). The study design, timeline and schematic diagram of the methodology are shown in Fig. 7A-585 
B. First, we used a live/dead assay to measure the viability of the slices. The results showed that there 586 
was no difference in the percentage of cells labelled by the cell death marker before and after lesioning 587 
the slices (8.4 ± 3.1 vs 4.6 ± 2.1%, p = 0.148, unpaired Student’s t test; Fig. 7C-D). We then treated the 588 
lesioned slices with S-220 being applied to the culture medium alone, or S-220 applied to the culture 589 
medium together with hydrogels (not containing S-220) being placed into lesion gaps (Fig. 7E-I). One-590 
way ANOVA showed that there was a significant treatment effect on axonal outgrowth across the lesion 591 
gap among different treatment groups [F(3,19) = 8.547, p=0.0006; Fig. 7G]. Thus, the results showed 592 
that the number of  β-tubulin-III staining profiles per mm2 per slice was significantly higher in the slices 593 
treated with the agonist and the gel when compared to those of the control, gel alone, and S-220 alone 594 
groups [S-220 + gel vs control, S-220 alone, and gel alone: 3016.5 ± 596.5 vs 821.8 ± 102.9 (p = 595 
0.00055), 1247.9 ± 73.7 (p = 0.005), and 1694.7 ± 82.9 (p = 0.0481), one-way ANOVA with 596 
Bonferroni’s post hoc; Fig. 7G].  597 
 598 
Epac2 agonist incorporated into Fmoc hydrogel promotes axonal outgrowth  599 
Our next step was to incorporate S-220 into the gel so that the agonist could be locally released and 600 
delivered to the injury site. Since it is a different delivery method, we tested different concentrations of 601 
the agonist in order to identify the optimal concentration. One-way ANOVA showed that there was a 602 
significant concentration effect on axonal outgrowth across the lesion gap [F(2,12) = 21.53, p = 0.00011; 603 
Fig. 8D]. Thus, the results  showed that the number of β-tubulin-III staining profiles per mm2 per slice 604 
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was significantly higher in the slices treated with the gel+S-220 (5 μM) in comparison to those of the 605 
gel+S-220 (2.5 μM) and gel+S-220 (10 μM) [gel+S-220 (5 μM) vs gel+ S-220 (2.5 μM) or gel+ S-220 606 
(10 μM): 3613.0 ± 177.0 vs 1457.6 ± 284.6 (p = 0.000091) or 2289.8 ± 298.2 (p = 0.0086), one-way 607 
ANOVA with Bonferroni’s post hoc test; Fig. 8A-D]. Once the optimal concentration of the agonist was 608 
established, we then investigated the efficacy of the agonist at this concentration when it was 609 
incorporated into the gel in promoting neurite outgrowth across the lesion gap. One-way ANOVA 610 
showed that there was a significant treatment effect on axonal outgrowth among different experimental 611 
groups [F(4,22) = 21.14, p = 7 x10-8; Fig. 8A-D]. Thus, the results showed that the number of β-tubulin-612 
III staining profiles per mm2 per slice was significantly higher in the slices treated with the gel+ S-220 613 
(5 μM) when compared to those of the control and gel only groups [gel+ S-220 (5 μM) vs control or gel 614 
only: 3613 ± 177 vs 743 ± 81.5 (p = 3 x10-8) or 1698.5 ± 169.4 (p=0.000003), Bonferroni’s post hoc; 615 
Fig. 8A-D]. 616 
 617 
The elevation of Epac2 activity attenuates the activation of astrocytes in an ex vivo model of SCI 618 
GFAP staining intensity within the lesion gap was quantified to assess astrocyte reactivity. A marked 619 
difference was found in the morphology of the astrocytes across the lesion gap from different 620 
experimental groups. GFAP immunoreactive cells at the forefront into the lesion gap in slices without 621 
any treatments were intensively labelled and hypertrophic (Fig. 8E). Slices treated with the gel only 622 
presented a mixed pattern of GFAP immunoreactive cells (Fig. 8F), while those slices receiving S-220 623 
treatment delivered by the gel presented GFAP immunoreactive cells that were lightly labelled and had 624 
elongated polygonal morphologies (Fig. 8G). One-way ANOVA showed that there was a significant 625 
treatment effect on GFAP activation across the lesion gap among different experimental groups [F(2,15) 626 
= 76.79, p = 1 x10-7; Fig. 8H]. Thus, the results showed that GFAP intensity in the slices treated with the 627 
agonist and the gel was significantly lower than those of the control or gel alone groups [gel+ S-220 vs 628 
control or gel only: 18.2 ± 1.1 vs 33.5 ± 0.5 (p = 8 x10-8) or 25.7 ± 0.9 (p = 0.00004), one-way ANOVA 629 
Bonferroni’s post hoc test; Fig. 8H]. We then performed double staining for β-tubulin-III and GFAP to 630 
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study the relationship between astrocytes (hypertrophic and non-hypertrophic) and regrown neurites. In 631 
non-treated slices highly reactive astrocytes appeared to act as a barrier for neurite outgrowth (Fig. 8I). 632 
Higher magnification images demonstrated collapsed growth cones when they confronted highly 633 
reactive astrocytes (Fig. 8J). Conversely, in the slices receiving S-220 delivered by the gel we observed 634 
a close relationship between β-tubulin-III stained neurite profiles and GFAP stained astrocyte processes 635 
(Fig. 8K). Higher magnification images demonstrated that regrown axons were indeed aligned to 636 
astrocyte processes (Fig. 8M). 637 
 638 
Overlapping of nestin and GFAP markers was also quantified as a reactivity parameter as previously 639 
described (O'Neill et al., 2017). One-way ANOVA showed that there was a significant treatment effect 640 
on nestin/GFAP overlapping across the lesion gap among different experimental groups [F (2, 16) = 641 
11.6, p = 0.0001; Fig. 8P]. Thus, the results showed that the mean nestin/GFAP overlapping pixels were 642 
significantly lower in the slices treated with S-220 delivered by the gel, when compared to those of the 643 
control or gel alone groups [gel + S-220 vs control or gel only: 48369.4 ± 16194.2 vs 140811.6 ± 644 
12992.8 (p = 0.003) or 141925.5 ± 19180.4 (p = 0.002), Bonferroni’s post hoc; Fig. 8N-P]. 645 
 646 
The elevation of Epac2 activity attenuates microglial activation in an ex vivo model of SCI 647 
We used the Iba-1 marker to identify microglia in lesioned slices. We found that, within the lesion            648 
site, Iba-1 immunoreactive cells displayed a highly activated morphology (large in cell size and with no 649 
processes) in those slices without any treatments (Fig. 9A, white asterisks). This activated morphology 650 
was in contrast to those Iba-1 immunoreactive cells located in the main body of the slices away from the 651 
lesion margins (Fig. 9C, yellow arrowheads) that exhibited a non-activated morphology (small in cell 652 
size and with ramified processes). However, we observed that in those slices treated with S-220 653 
delivered by the gel, Iba-1 immunoreactive cells within the lesion site resembled the non-activated 654 
morphology seen in the main slice body (Fig. 9B, yellow arrowheads). We then performed a 655 
quantification to determine the differences in Iba-1 immunoreactive cells within the lesion site among 656 
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different experimental groups by measuring cell body perimeter, which has been shown to correlate with 657 
microglial activation (Kozlowski and Weimer, 2012). Thus, the results showed that the mean cell body 658 
perimeter of Iba-1 immunoreactive cells per slice was significantly smaller in the slices treated with S-659 
220 and the gel in comparison to those of the control or gel alone groups [gel + S-220 vs control or gel 660 
alone: 93 ± 4.2 vs 123.7 ± 1.7 μm (p = 0.000091) or 103.1 ± 2.3 μm (p = 0.0086), Bonferroni’s post hoc 661 
test; Fig. 9D]. In those slices receiving S-220 delivered by the gel we found that the mean cell body 662 
perimeter of Iba-1 immunoreactive cells was similar to that of non-activated microglia seen in the main 663 
slice body (gel + S-220 vs non-activated microglia in the main slice body: 93 ± 4.2 vs 81.7 ± 2.4 μm, p = 664 
0.115, unpaired Student’s t test; Fig. 9D]. The relationship between GFAP immunoreactive and Iba-1 665 
immunoreactive cells was investigated by examining the co-labeling of these two markers. In non-666 
treated slices, we observed that highly reactive astrocytes were intermingled with large, amoeboid and 667 
congregated Iba-1 immunoreactive cells (Fig. 9E), demonstrating that both activated glial cells formed a 668 
highly inhibitory environment for neurite outgrowth. In contrast, in the slices receiving S-220 delivered 669 
by the gel we observed smaller non-activated Iba-1 immunoreactive cells, which were sparsely spread 670 
around elongated polygonal GFAP immunoreactive cells (Fig. 9F). 671 
 672 
S-220 delivered by Fmoc hydrogel promotes functional recovery after a spinal cord contusion injury 673 
Injured rats treated with S-220 delivered by the gel at three weeks post-surgery showed significant 674 
improvement in the BBB score, already detectable three weeks after treatment compared to injury-only 675 
controls, indicating better controlled limb movements after treatment with S-220-loaded gels (Fig. 10). 676 
The improvements were sustained for the rest of the study. Two-way ANOVA showed that there was 677 
significant treatment effects [F (1,35) = 16.17, p < 0.001; Fig. 10]. At week four post-treatment, 678 
contused rats that received S-220-loaded gel significantly increased locomotor behavior reaching an 679 
average BBB score of 17.3 ± 0.9, compared to 14.3 ± 1.1 for injury-only controls (p = 0.042, 680 
Bonferroni’s post hoc analysis; Fig. 10). 681 
 682 
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Discussion 683 
 684 
Promoting injured adult CNS mammalian neurons to regrow after injury remains a significant 685 
challenge in modern medicine. Among different strategies, cAMP and its downstream effectors 686 
have been shown to enhance neurons’ outgrowth capacity. Here, we demonstrate for the first time, 687 
using pharmacological and genetic tools, that specific elevation of Epac2 activity, a downstream 688 
target of cAMP, significantly enhances neurite outgrowth of cultured postnatal DRG and cortical 689 
neurons. Moreover, Epac2 activation promotes significant axonal outgrowth in lesioned spinal cord 690 
slices in an ex vivo model of SCI. We reveal novel evidence that Epac2 elevation overcomes 691 
inhibition on neuron/axon growth by CSPGs and mature astrocytes in vitro and by the post-lesion 692 
environment of the ex vivo model. 693 
 694 
Previously PKA was thought to be solely responsible for cAMP’s effects on axonal growth (Siddiq 695 
and Hannila, 2015). However, strong evidence suggests that it is Epac, not PKA, that mediates the 696 
positive effects of cAMP in promoting axonal growth (Murray et al., 2009; Boomkamp et al., 2014; 697 
Wei et al., 2016). Several general agonists were developed to activate Epac, but not PKA, allowing the 698 
study of Epac’s roles in mediating specific cAMP functions in cell signaling pathways (Enserink et al., 699 
2002). Studies using these agonists demonstrate that Epac mediates cAMP-dependent axonal 700 
growth in: (1) embryonic, neonatal and adult rat DRG neurons (Murray and Shewan, 2008; Murray 701 
et al., 2009; Wei et al., 2016), (2) PC12 cells (Christensen et al., 2003); and (3) an in vitro model of 702 
SCI and remyelination (Boomkamp et al., 2014). These agonists also regulate axonal elongation in rat 703 
embryonic hippocampal neurons (Munoz-Llancao et al., 2015), and switch the proliferative signal of 704 
cAMP to a neuronal differentiation program in PC12 cells (Kiermayer et al., 2005). However, they 705 
failed to discriminate the effects between Epac1 and Epac2. 706 
 707 
We previously showed that siRNA knockdown of Epac1 and Epac2 in adult DRG neurons 708 
significantly reduced neurite outgrowth (Murray and Shewan, 2008). However, since adult neurons 709 
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mainly express Epac2, our previous evidence on neurite growth is likely to be mediated solely by 710 
Epac2. Here, we used an Epac2 specific agonist (S-220), which has been shown to selectively 711 
activate Epac2 (Schwede et al., 2015). We are the first group to report the use of this agonist in 712 
primary postnatal rat neurons and spinal cord tissue. Indeed, we used FRET to demonstrate that S-713 
220 enhanced Epac2 protein activity in the growth cones of DRG neurons. Furthermore, we 714 
provided direct evidence that DRG neurons turned towards a gradient of S-220, such that Epac2 715 
activation was biased towards the direction of turning. These data convincingly suggest the 716 
specificity of this agonist in postnatal neurons. We and others have previously reviewed potential 717 
mechanisms of Epac2 signaling in neurite outgrowth (Peace and Shewan, 2011a; Batty et al., 2017). 718 
Thus, Epac2 is known to activate Rap1, which can subsequently modulate AKT (Mei et al., 2002; 719 
Nijholt et al., 2008) and B-Raf-MER-ERK (Qiu et al., 2000; Enserink et al., 2002; Wang et al., 720 
2006) signaling pathways, both being shown to play essential roles in axonal growth and guidance 721 
(Liu and Snider, 2001). Epac2 activation may also lead to CREB activation that has been shown to 722 
promote neuroplasticity (Wei et al., 2016) (Fig. 11).  723 
 724 
Following SCI, there are numerous molecules present at the lesion site, including CSPGs, MAG, 725 
Nogo, and OMgp that are inhibitory to axonal outgrowth (Hannila and Filbin, 2008). A body of 726 
evidence has shown that elevation of neuronal cAMP level overcomes the inhibition by MAG and 727 
CNS myelin on axonal outgrowth (Siddiq and Hannila, 2015). The ability of cAMP elevation to 728 
overcome inhibition may involve the activation of CREB, which then leads to transcriptional 729 
changes in arginase I, interleukin-6, secretory leukocyte protease inhibitor, and metallothionein 730 
(Hannila and Filbin, 2008; Siddiq and Hannila, 2015). Up-regulation of these genes has been shown 731 
to promote axonal outgrowth (Cafferty et al., 2004; Deng et al., 2009; Ghasemlou et al., 2010; 732 
Siddiq and Hannila, 2015). Here, we report that activation of Epac2 overcomes inhibition by 733 
CSPGs and mature astrocytes on neuronal growth, and this could therefore be mediated through 734 
CREB activation. It is important to note that Rap1 can regulate integrins, which are essential for cell 735 
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adhesion (Bos et al., 2003). Different cell types have been shown to control adhesion to laminin via 736 
cAMP-mediated integrin regulation (Murphy et al., 2005). Therefore, Epac2 activation could 737 
possibly also lead to Rap1-mediated redistribution and conformational activation of integrins in the 738 
growth cone (Bos et al., 2003), thereby modifying their responses to inhibitory molecules in the 739 
extracellular matrix after injury (Condic et al., 1999; Tan et al., 2011; Cheah and Andrews, 2018). 740 
 741 
Apart from the effects on axonal outgrowth in the ex vivo model, we also report a significantly 742 
modified lesion environment consisting of astrocytes and microglia by the Epac2 agonist. 743 
Astrocytes form the major cell type that contribute to the formation of the glial scar after SCI and 744 
strong evidence suggests that there is heterogeneity within astrocyte populations in the scar with 745 
some cells producing axon-growth supporting molecules (Anderson et al., 2016). The morphology 746 
of Epac2 agonist-treated astrocytes in our study remarkably resembles those newly proliferated and 747 
elongated astrocytes at the lesion border after SCI, which are regulated by the STAT-3 signaling 748 
pathway (Wanner et al., 2013) and show similarity with radial glial progenitors providing guidance 749 
for neuron growth during CNS development (Garcia et al., 2004). Although the functions of these 750 
elongated astrocytes at the lesion border are largely unclear, evidence suggests that they regulate 751 
inflammatory cell behavior (Wanner et al., 2013). Here, we demonstrate a similar pattern following 752 
S-220 treatment, in that elongated astrocytes exist among Iba-1+ microglia with non-activated 753 
morphology at the lesion site. It is known that cAMP elevation can cause autocrine interleukin-6 754 
up-regulation in astrocytes, which in turn can lead to STAT3 phosphorylation (Takanaga et al., 755 
2004). Moreover, cAMP elevation in astrocytes causes morphological change into a process-756 
bearing shape, downregulation of the genes responsible for proteoglycan production, and up-757 
regulation of the gene for the NMDA receptor subunit NR2C that is a major component of the 758 
tripartite synapse regulating astrocyte-neuron communication (Paco et al., 2016). Therefore, it is 759 
conceivable that in our study the S-220 has caused profound changes in astrocytes at the lesion site 760 
similar to those described after cAMP elevation and render them supportive for the regrowing axons 761 
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(Fig. 11). Furthermore, there is evidence that cAMP elevation by a general agonist causes 762 
microglial BV-2 cells to increase arginase I production and change to bipolar morphology when co-763 
treated with TNF-D (Ghosh et al., 2016). Epac activation by a general agonist also causes BV-2 764 
cells to reduce their pro-inflammatory activities (Steininger et al., 2011). Hence, we propose that in 765 
our study the S-220 also attenuates the activation of microglia at the lesion site. Taken together, our 766 
data suggest that Epac2 elevation in both astrocytes and microglia may have potently modified the 767 
lesion environment from inhibitory to permissive for axonal outgrowth.  768 
 769 
With the novel Fmoc-based hydrogel used as a delivery depot for sustained release of S-220, our 770 
study confers translational potential. We demonstrate for the first time that this hydrogel has 771 
excellent biocompatibility and supports excellent neurite outgrowth in vitro and axonal outgrowth 772 
in the ex vivo model. Moreover, its stiffness can be tuned to be similar to CNS tissue properties, 773 
which is a key requirement for spinal cord repair (Georges et al., 2006). Furthermore, the hydrogel 774 
can be developed as injectable formats that can fully plug lesion cavities, thus representing a 775 
minimally invasive neurosurgical technique (Cigognini et al., 2011; Kabu et al., 2015). In an 776 
exploratory pilot study, we injected the S-220 loaded Fmoc hydrogel into the lesion cavity of rats 777 
with contusion SCI at a subacute stage i.e. 3 weeks post-injury and found significantly improved 778 
locomotor functional recovery when compared with animals with contusion only. However, further 779 
in vivo immunohistochemical and functional studies are required to validate the potential of these 780 
treatments in SCI, which is beyond the scope of the current study. Future studies also need to 781 
further optimize the injected hydrogel volume and S-220 dose and establish the in vivo effects of S-782 
220 on axonal outgrowth and glial activation.   783 
 784 
The failure to find a cure for spinal cord repair is mainly due to the complex injury nature of SCI. 785 
Many studies have designed strategies, either alone or in combination, to tackle various obstacles 786 
presented by the injury, but so far have failed to translate results to the clinic. Our findings using 787 
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Epac2 elevation to promote spinal cord repair underpin a significant game change not only in 788 
directly enhancing the intrinsic capacity of injured neurons to regrow, but moreover in harnessing 789 
the inhibitory environment, including the glial scar and microglia, to facilitate axonal outgrowth. 790 
However, caution is needed when extrapolating our strategy to other CNS injuries such as brain 791 
injury and stroke, as recent preclinical evidence suggests that, in the acute phase of hemorrhage-792 
induced brain trauma, increased neuronal expression of Epac2 leads to apoptosis (Zhuang et al., 793 
2019). Future studies are required to fully understand the role of Epac2 under different CNS injury 794 
pathogeneses. 795 
 796 
 797 
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Figure Legends 996 
 997 
Fig. 1: The effects of Epac2 modulation on cortical neurite outgrowth. A–C, Epac2 agonist S-998 
220 promoted significant neurite outgrowth (A, control. B, treated with S-220. C, 999 
quantification of total neurite length shows that S-220 treated neurons had significantly 1000 
longer neurites). D-F, Epac2 antagonist ESI-05 significantly decreased cortical neurite 1001 
outgrowth (D, control. E, treated with ESI-05. F, Quantification of total neurite length shows 1002 
that ESI-05 treated neurons had significantly shorter neurites). G-I, siRNA knockdown of 1003 
Epac2 significantly decreased cortical neurite outgrowth (G, scrambled siRNA control. H, 1004 
Epac2 siRNA treated. I, quantification of total neurite length shows that Epac2 siRNA treated 1005 
neurons had significantly shorter neurites). J-L, Overexpression of Epac protein using 1006 
lentivirus promoted cortical neurite outgrowth (J, LV/GFP transduced neurons. K, LV/Epac-1007 
YFP transduced neurons. L, quantification of total neurite length shows that LV/Epac-YFP 1008 
transduced neurons had significantly longer neurites). A, B, D and E cultures were grown for 1009 
24 h. G-H cultures were grown for 48 h. J-K cultures were grown for 7 days to allow enough 1010 
time for gene expression. All cultures were immunostained for β-tubulin-III. Unpaired 1011 
Student’s t test, n = 3/group. Data expressing mean ± SEM. Scale bar: A- E, J-K: 50 μm; G-1012 
H: 100 μm.  1013 
 1014 
Fig. 2: Epac agonist activates Epac protein in DRG growth cones and induces growth cone 1015 
attraction. A-D, representative images of FRET SE before (A) and after (B) the addition of 1016 
the Epac2 agonist S-220 and before (C) and after (D) the addition of the Epac2 antagonist 1017 
ESI-05. E, FRET SE measured over time shows a significant activation and inactivation of 1018 
Epac after the addition of the S-220 (blue) and ESI-05 (red), respectively, compared to 1019 
control (black) (n = 4). F-G, representative images of DRG growth cones turning towards a 1020 
 42 
 
gradient of S-220 at time 0 (F) and 30 min (G). H, Cumulative frequency plots of turning 1021 
angles show a clear switch towards the right in gradients of S-220 (blue) compared to control 1022 
F12 (black), indicating greater attraction towards the direction of Epac2 activity. Average 1023 
turning angles are shown above the abscissa (n = 10). Data expressing mean ± SEM. Scale 1024 
bars: A-D = 10 μm; F-G = 50 μm. 1025 
 1026 
Fig. 3: The Epac2 agonist overcomes inhibitory environments for cortical neuron growth. A, 1027 
β-tubulin-III positive cortical neurons grew neurites on PDL coated coverslips; B, cortical 1028 
neurons treated with CSPGs showed significantly shorter neurite lengths compared to control. 1029 
C, Epac2 agonist S-220 attenuated the inhibitory effect of CSPGs on cortical neurite 1030 
outgrowth. D, Quantification represents the percentage of change from control and shows a 1031 
significant reduction in inhibition by CSPGs when S-220 was simultaneously applied. 1032 
Cultures were grown for 48 h. E-G, S-220 also showed the effect in overcoming the astrocyte 1033 
inhibition. Three neurite growth cone behaviors of DRG neurons co-cultured with mature 1034 
astrocytes were observed: retract ( in E), reflect (* in E) and crossover (# in F) using time-1035 
lapse live cell microscopy. G, the quantification showed a significant reduction in the 1036 
retract/reflect behaviors of neurites and a significant increase in the crossover behavior of 1037 
neurites in cells treated with the Epac 2 agonist when compared to control. D, G, Mann-1038 
Whitney Rank Sum test, n = 3/group.  Data expressing mean ± SEM. Scale bars, A-C = 50 1039 
μm; E-F = 25 μm. 1040 
 1041 
Fig. 4: Epac2 agonist S-220 attenuates LPS induced astrocyte and microglial activation in 1042 
vitro. Representative fluorescent images of control (A), LPS-treated (B) and LPS + S-220-1043 
treated (C) astrocytes. Representative fluorescent images of control (D), LPS-treated (E) and 1044 
LPS + S-220-treated (F) microglia immunostained for Iba-1 (green) and iNOS (red). G, 1045 
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Quantification of the mean fluorescence intensity of GFAP showed significant difference 1046 
between control and LPS-treated astrocytes, and between LPS and LPS + S-220-treated 1047 
astrocytes. H, Quantitative image analysis showing significant differences in iNOS 1048 
immunoreactive cell numbers among control, LPS-treated and LPS + S-220-treated 1049 
microglia. I, Greiss assay demonstrated a significant increase of nitrate concentration in the 1050 
supernatant collected from LPS-treated microglial cultures when compared to that of the 1051 
control. Data expressing mean ± SEM. n = 3/group. One-way ANOVA with Bonferroni post 1052 
hoc test. Scale bars: 100 μm. 1053 
 1054 
Fig. 5: The hydrogel degrades gradually, induces minimal immune response and supports 1055 
marked neurite outgrowth in 2D cultures. A, An image of a freshly prepared gel. B, The 1056 
Griess assay showed low levels of nitrite in gel culture media compared to that of LPS-1057 
exposed primary microglia cultures. C, Gel stiffness showed a gradual decrease in gain 1058 
modulus from the linear region of the raw data (0 to 100 Hz, rheology). D, In vitro 1059 
cumulative percentage drug release versus time profile. Optimization of RGD concentration 1060 
to promote neurite outgrowth of DRG explants in two dimensions. E, DRG explant in gel 1061 
without RGD. F, DRG explant in 1.6 mM RGD gel. G, Quantification of maximal distance of 1062 
neurite outgrowth showed significant differences at 1.6 mM and 3.2 mM RGD compared to 1063 
control. H, Quantification of neurite densities of DRG explants at different concentrations of 1064 
RGD. I, Cortical neurons on gel without RGD. J, Cortical neurons on gel with 1.6 mM RGD. 1065 
K, quantification of neurite length in gels with and without RGD, showing significantly 1066 
enhanced neurite outgrowth on gels with 1.6 mM RGD. L, DRG explants grew extensive 1067 
neurites in three dimensions within the gel with 1.6 mM RGD at 72 h after plating. M, Z-1068 
stack image of DRG neurons growing in three dimensions within the 1.6 mM RGD gel). N, Z 1069 
plane view of DRG neurons. DRG explants were immunostained for GAP-43 (E-F). DRG 1070 
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neurons and cortical neurons were immunostained for β-tubulin III (I-J, M-N). Data 1071 
expressing mean ± SEM, n = 3/group. Scale bars, E-F = 200 μm; I, J and L = 100 μm; M = 1072 
50 μm. One-way ANOVA with Bonferroni’s post hoc (B, D, G-H), Kruskal-Wallis ANOVA 1073 
on Ranks with Tukey post hoc (C) and unpaired Student’s test (K). 1074 
 1075 
Fig. 6: In vitro evidence demonstrating the positive effects of combining the Fmoc hydrogel 1076 
with Epac2 agonist application on neurite outgrowth. A-C, Assessing the effect of combining 1077 
the Fmoc hydrogel with the Epac2 agonist S-220 in enhancing neurite outgrowth of DRG 1078 
explants. A, Control explant growing in gel alone. B, Explant growing in gel in combination 1079 
with S-220. C, Quantification of the maximal neurite length showed significantly longer 1080 
neurites in the combination treatment group than the gel-only group. D-F, Assessing the 1081 
effect of combining the gel with S-220 in enhancing neurite outgrowth of dissociated DRG 1082 
neurons. D, DRG neurons growing in gel alone. E, DRG neurons growing in gel in 1083 
combination with S-220. F, Quantification of the maximal neurite length showed 1084 
significantly longer neurites in the combination treatment group than the gel-only group. Data 1085 
expressing mean ± SEM. Scale bars, A = 250 μm; B = 500 μm; D-E = 100 μm. Unpaired 1086 
Student’s t test, n = 3/group.  1087 
 1088 
Fig. 7: Timeline, study design and schematic diagram of ex vivo preparation on organotypic 1089 
spinal cord culture. A, Timeline of the experiments. B, Schematic diagram depicting the 1090 
production and lesioning of organotypic spinal cord slice cultures. C, Quantification of 1091 
live/dead assay did not show any difference before and after lesion (n = 10-15/group). D, 1092 
Representative lived/dead-stained fluorescence micrograph of a slice before lesioning and 2 1093 
days post-lesion. E-I, Using the ex vivo model we found that, at 7 days post-injury, treatment 1094 
with either S-220 or hydrogel alone produced similar degrees of neurite outgrowth into the 1095 
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lesion gaps, but significantly more than that of the non-treated slices (E, non-treated slice; F, 1096 
S-220- treated slice; H, hydrogel treated slice; I, combination treated slice; white dashed lines 1097 
indicate lesion margins). The agonist was added to culture media. G, The axonal profile 1098 
analysis showed that, when the gel was combined with S-220, there was significantly more 1099 
axon growth in the lesion gap than those following treatments with S-220 or hydrogel alone. 1100 
C, Data expressing mean ± SEM. G, Data expressing mean ± SEM (box limits), bars above 1101 
and below each box = 5% & 95% confidence limits. Circles represent individual biological 1102 
replicates (n = 4 - 6). One-way ANOVA, Bonferroni’s post hoc test. Scale bars, D = 500 μm; 1103 
E-I = 200 μm. 1104 
 1105 
Fig. 8: S-220 incorporated into the hydrogel promotes neurite outgrowth and suppresses 1106 
astrocyte activation. A-B, Representative images showing significant difference in neurite 1107 
outgrowth between gel only (A) and gel + 5μM S-220 (B). White dashed lines indicate lesion 1108 
margins. C, Neurite growth profiles across the lesion gap, showing a progressive increase 1109 
with gel only and gel + 5 μM S-220. D, Quantification showing the numbers of β-tubulin III+ 1110 
processes per mm2 between control and different concentrations of S-220 delivered in the gel, 1111 
with 5μM having the greatest effect. E-G, Representative images exhibit astrocyte activation 1112 
in the lesion using GFAP staining as an astrocyte marker. E, Control. F, Gel only. G, Gel + 1113 
5μM S-220. H, Quantification of the GFAP immunoreactivity intensity showed a significant 1114 
reduction of mean grey value (OD) in gel + 5μM S-220 compared to the control and the gel 1115 
only treatment. I, Representative image of the relationship between GFAP (red) and β-1116 
tubulin-III (green) immunoreactive processes in a control injury condition. J, Higher 1117 
magnification image showing the collapse of growth cones (white arrowheads) when they 1118 
meet activated astrocytes. K, Representative image of the relationship between GFAP and β-1119 
tubulin-III immunoreactive processes in a lesion with combined treatment with gel + 5 μM S-1120 
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220. M, Higher magnification image showing the alignment of the astrocytes and β-tubulin-1121 
III immunoreactive processes (white arrowheads). N-O, Levels of astrocyte reactivity were 1122 
estimated by the overlapping of GFAP (red) and nestin (green). N, Representative image of 1123 
GFAP/nestin reactivity in lesion sites of non-treated slices. O, Representative image of 1124 
GFAP/nestin overlapping in slices treated with S-220 delivered by the hydrogel. P, 1125 
Quantification of GFAP/nestin pixel overlapping. Data in D, H and P are expressed as mean 1126 
± SEM (box limits). Bars above and below each box = 5% & 95% confidence limits. Circles 1127 
represent individual biological replicates (n = 4-6). One-way ANOVA with Bonferroni’s post 1128 
hoc test. Scale bars, A-B, E-G and N-O = 100 μm; I, K = 50 μm; J, M = 25 μm. 1129 
 1130 
Fig. 9: S-220 incorporated into the gel suppresses microglia activation in lesioned spinal cord 1131 
slice. A, Iba-1 immunoreactive cells inside the injury site in control lesion slices (white 1132 
asterisks, indicating activated morphology). B, Iba-1 immunoreactive cells inside the injury 1133 
site in combination treated slices (yellow arrowheads, indication resting morphology). C, 1134 
Non-injured microglia (yellow arrowheads, indicating resting morphology). D, Cell body 1135 
perimeter was quantified and used as an indication of activation. Cell body size decreased 1136 
more significantly in the presence of the hydrogel only or hydrogel + 5 μM S-220, 1137 
respectively. E, Representative image of the relationship between GFAP and Iba-1 1138 
immunoreactive cells in an injured control. F, Representative image of the relationship 1139 
between GFAP and Iba-1 immunoreactive cells in injured slices treated with a combination 1140 
of hydrogel + 5 μM S-220. Data in D are expressed as mean ± SEM (box limits). Bars above 1141 
and below each box = 5% & 95% confidence limits. Circles represent individual biological 1142 
replicates (n = 4). One-way ANOVA with Bonferroni’s post hoc test. Scale bars, A-C = 25 1143 
μm; E-F = 50 μm. 1144 
 1145 
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Fig. 10: S-220 delivered by Fmoc hydrogel into the lesion of contusion injured spinal cord 1146 
enhances locomotor functional recovery. Both S-220-treated and non-treated contusion-1147 
injured animals showed similar levels of locomotor function at 3 weeks post-injury as 1148 
assessed on the BBB open field task. However, by 2 weeks after treatment (indicated by the 1149 
black arrow), S-220-treated animals showed significantly better locomotor function (3 points 1150 
on the BBB scale) compared with the non-treated animals, a difference was maintained until 1151 
4 weeks after treatment (the last time point assessed). Data were analyzed with two-way 1152 
ANOVA followed by Bonferroni’s post hoc test. n = 4-5. Data were expressed as mean ± 1153 
SEM. * p < 0.05. 1154 
 1155 
Fig. 11: A schematic diagram summarizing the potential mechanisms of Epac2 activation by 1156 
S-220 in the in vitro and ex vivo studies. The blue dotted rectangle and blue dotted arrows 1157 
summarizes the mechanisms for in vitro studies. The red dotted rectangle and red dotted 1158 
arrows summarizes the mechanisms for ex vivo studies. Our findings from the in vitro studies 1159 
with individual monocultures of neurons, astrocytes, and microglia demonstrate that S-220 1160 
has direct and individual effects on: (a) neurons, promoting their growth possibly via the 1161 
subsequent activation of Rap-1/B-Raf/ERK signaling pathway (Murray and Shewan, 2008; 1162 
Murray et al., 2009; Wei et al., 2016); (b) astrocytes, reducing their activation by LPS 1163 
possibly via IL-6/STAT3 signaling pathway (Takanaga et al., 2004); and (c) microglia, 1164 
reducing their activation by LPS possibly via arginase I signaling pathway (Ghosh et al., 1165 
2016). S-220 binds to the cyclic nucleotide binding (CNB) domains of Epac2 protein within 1166 
these cells triggering downstream signaling pathways (Tucker, 2014). Our findings from the 1167 
ex vivo studies, however, suggest that S-220 manifests its effects on these cells in a more 1168 
complex and intermingled manner: (1) elongated astrocytes following S-220 treatment may 1169 
resemble radial glial progenitors, releasing axon-growth supporting molecules (Garcia et al., 1170 
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2004); (2) elongated astrocytes following S-220 treatment may provide direct guidance for 1171 
axonal growth (Anderson et al., 2016); (Robichaux and Cheng) reduced astrocyte activation 1172 
by S-220 may lead to upregulate the gene for NMDA receptor subunit NR2C, which is a key 1173 
part in the tripartite synapse regulating astrocyte-neuron communication (Paco et al., 2016); 1174 
(4) reduced astrocyte activation by S-220 may down-regulate the genes responsible for the 1175 
production of proteoglycans including CSPGs, thereby reducing their inhibitory effects on 1176 
axonal outgrowth (Paco et al., 2016); (5) reduced astrocyte activation by S-220 may involve 1177 
STAT-3/nestin, and subsequently may regulate other inflammatory cell behavior, such as that 1178 
of microglia at the spinal cord lesion site (Wanner et al., 2013); and (6) reduced microglial 1179 
activation via astrocyte regulation may lead to reduced production of proinflammatory 1180 
mediators (Steininger et al., 2011), thereby promoting axonal outgrowth. It is also highly 1181 
likely that S-220 may have direct and individual effects on these three types of cells in the ex 1182 
vivo model, including transcriptional changes in arginase I, interleukin-6, secretory leukocyte 1183 
protease inhibitor, and metallothionein in neurons (d) (Hannila and Filbin, 2008; Siddiq and 1184 
Hannila, 2015), which have been shown to promote axonal outgrowth and overcome 1185 
inhibitory molecules. Red and blue small circles with diagonal across = stop/inhibit. 1186 











